fda warning letters glp-1 october 2025 news September 15, 2025: Telehealth company must stop implying its compounded GLP -1 is FDA-approved, warns – Partnership for Safe Medicines FDA Drug Recalls and Warnings:

Multi-vial discounts Most research peptide vendors offer tiered pricing for bulk orders

At Skyway, we emphasize trauma-informed care, client autonomy, and a holistic approach, ensuring that each treatment plan aligns with clients unique needs and recovery goals

But as an example, in the original dataset, 51.9% of those who got Mounjaro had diabetes compared with 71.5% of those who got Ozempic

In a 2023 animal and laboratory study, researchers suggested that GLP-1 medications could have the following benefits for people with UC: lowering the levels of proinflammatory mediators chemicals that cause inflammation preventing certain important proteins and pathways in the body from becoming overactive, which can contribute to UC repairing damage to the inner lining of the intestines improving the balance of good bacteria in the gut The researchers suggested that GLP-1 medications may be a promising future treatment for UC

Who It's For (Based on Trial Inclusion Criteria) BMI 30 (obesity) OR BMI 27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, high cholesterol, sleep apnea) Adults ages 1875 (some trials include narrower age ranges) People who have tried lifestyle interventions (diet and exercise) without sufficient weight loss Those with type 2 diabetes seeking both glucose control and weight loss People with obesity-related conditions that would improve with major weight reduction Who Should Avoid Retatrutide Based on trial exclusion criteria and the drug's mechanism, retatrutide is likely not appropriate for: Pregnancy or breastfeeding: Not studied in these populations